慢性肾病（CKD）患者中无症状高尿酸血症的治疗缺乏有效药物。研究人员开展了关于 Febuxostat 对 3、4 期 CKD 合并无症状高尿酸血症患者疗效的研究。结果显示，Febuxostat 能降低血尿酸水平、稳定 eGFR。这为相关疾病治疗提供了新方向。 在医学领域，慢性肾病（CKD ...

2023年5月25日，英国药品和医疗产品监管署（MHRA）发布最新药物安全性信息，内容涉及“在伴主要心血管疾病病史患者中，非布司他（Febuxostat ...

尤为重要的是，RUZINURAD与XOI代表药物febuxostat联用时，在降低sUA上显现出了显著的协同效应，进一步增强了治疗潜力。 在即将召开的2024欧洲风湿病学 ...

A new study published in the journal of Arthritis Care & Research showed that in individuals with gout, usage of Febuxostat ...

If you have a history of cardiovascular disease, you should only use febuxostat to treat your gout in two situations. The first is if you’re not able to take the gout drug allopurinol.

Am J Health Syst Pharm. 2011;68(5):389-398. Gout flares typically begin abruptly, with red, hot, or tender joints. Individuals may also be febrile during gouty attacks. Attacks may be ...

Credit: Getty Images. Major effects of febuxostat on renal outcome might be uric acid dependent, according to investigators. Beside reducing serum uric acid in patients with chronic kidney disease ...

Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with ...

Risk of death from all causes was similarly lower for patients on hemodialysis prescribed either allopurinol or febuxostat. Risk of CVD-related death was lower for those on allopurinol ...

Febuxostat is a xanthine oxidase (XO) inhibitor, prescribed for gout and hyperuricemia (high level of uric acid in blood). The serum concentration of the active metabolites of Ambroxol ...